Rangarira ndima iri pasi apa uye ipapo pindura mubvunzo gare gare mumutauro mumwe chetewo sechikamu:  Passage: Kubva muna 2019, mishonga gumi nembiri inoshandura chirwere inobvumidzwa nemasangano anodzora kurapwa kwechirwere che multiple sclerosis (RRMS). Iwo interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, ocrelizumab, siponimod, uye cladribine. Kubudirira kwemari yavo kubva muna 2012 hakuna kujeka. Muna Kurume 2017 FDA yakabvumidza ocrelizumab, humanized anti-CD20 monoclonal antibody, senzira yekurapa RRMS, nezvinodiwa kune akati wandei Phase IV kliniki miedzo. MuRRMS ivo vane mwero vanobudirira mukuderedza huwandu hwekurwiswa. Mainterferon ne glatiramer acetate ndiwo marapiro okutanga uye anenge akaenzana, achideredza kudzokororwa kwechirwere ne30%. Kurapa kwenguva refu kunotanga nokukurumidza kwakachengeteka uye kunovandudza migumisiro. Natalizumab inoderedza mwero wekudzoka zvakanyanya kupfuura mishonga yekutanga; zvisinei, nekuda kwemibvunzo yemigumisiro yakaipa, mushonga wechipiri wakagadzirirwa kune avo vasingateereri kumwe kurapwa kana nechirwere chakakomba. Mitoxantrone, iyo kushandiswa kwayo kwakaganhurirwa nemigumisiro yakakomba yakaipa, isarudzo yomutsara wechitatu nokuda kwaavo vasingapinduri kumimwe mishonga. Kurapa kwechirwere chakasarudzika chirwere (CIS) nema interferon kunoderedza mukana wekufambira mberi kuenda kuchipatara MS. Kubudirira kwema interferon uye glatiramer acetate muvana kwave kuchifungidzirwa kunge kwakaenzana neyavakuru. Basa remamwe mishonga mitsva yakadai se fingolimod, teriflunomide, uye dimethyl fumarate, kubva muna 2011, haisati yajekeswa zvizere. Kubva muna 2017, rituximab yaishandiswa zvakanyanya kurapa RRMS.  Mubvunzo: Inferone ipi inotanga kutaurwa?
interferon beta-1a